Navigation Links
Hormonal male contraception reversible after few months for all men

With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of THE LANCET highlight how such contraception is reversible within a few months.

Currently available male contraceptive methods (condoms, withdrawal, and vasectomy) are not acceptable to many couples because they are either not sufficiently reliable or not easily reversible. In a similar way to ovulation suppression by hormone treatment in women, sperm production can be fully inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone treatment, azoospermia (no sperm in ejaculate) or severe oligozoospermia (less than 3 million sperm per mL of semen), which is sufficient for contraceptive purposes, can be achieved. Currently, a large phase III study with an androgen treatment and a large, multicentre phase II study of androgen-progestagen combinations are being completed in China and Europe, respectively.

Peter Liu from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), who is currently located at the ANZAC Research Institute, University of Sydney, Australia, and colleagues analysed data from individual participants in 30 studies published in 1990?005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility.

Data were available for around 1500 men. The average time for sperm recovery to 20 million/mL was 3? months. Various factors were associated with higher rates of recovery including older age, Asian origin, shorter treatment duration, and higher sperm concentrations at baseline. Although these factors modulated the speed of recovery, spermatogenesis recovered to levels compatible with fertility in all men.

Dr Liu and colleagues comment: "Our data provide strong assurance that the previously described eff icacy of hormonal male contraceptives is coupled with highly predictable recovery to semen characteristics that are compatible with fertility. These findings thereby increase the promise of new contraceptive drugs allowing men to share more fairly the satisfaction and burden of family planning."


'"/>

Source:Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)


Related biology news :

1. Emergency contraception fails to halt abortions
2. Male contraception: One door opens, another closes
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Rewind, please: Nature paper shows that cell division is reversible
5. First-degree fetal heart block may be reversible
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
(Date:2/3/2016)... 3, 2016   ViaCyte, Inc ., a ... pluripotent stem cell-derived islet replacement therapy for the ... today announced that ViaCyte and Janssen Biotech, Inc., ... & Johnson, have agreed to consolidate the assets ... agreement provides ViaCyte with an exclusive license to ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
Breaking Biology Technology: